69 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    Diana Castro, MD - Altering the Natural History of Spinal Muscular Atrophy: A Compelling Story Highlighting the Critical Role of Presymptomatic Treatment

    Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy

    • 24 min
    • video
    Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

    Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

    Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

    • 23 min
    • video
    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis

    • 11 min
    • video
    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies

    • 39 min
    • video
    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

    • 1 hr 30 min
    • video
    Robin L. Jones, MD - Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science

    Robin L. Jones, MD - Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science

    Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don’t miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

    • 57 min

Top Podcasts In Science

Listeners Also Subscribed To